SCYNEXIS (SCYX) vs TherapeuticsMD (TXMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
TherapeuticsMD (TXMD) has outperformed SCYNEXIS (SCYX) over the past year, gaining 89.6% versus a loss of 32.1%. Over five years, SCYX leads with a -90.5% price change compared with -94.4% for TXMD. SCYNEXIS is the larger company by market cap ($42.0 million vs $23.3 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCYX | TXMD |
|---|---|---|
| Share price | $4.22 | $2.01 |
| Market cap | $41.99M | $23.26M |
| 1-day change | -11.72% | +0.50% |
| YTD return | -16.53% | +23.31% |
| 1-year return | -32.11% | +89.62% |
| 5-year return | -90.53% | -94.42% |
| Forward P/E | — | 5.74 |
| EPS (TTM) | $-0.89 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.12 | $2.95 |
| 52-week low | $3.53 | $1.03 |
| Distance from 52-week high | -53.73% | -31.86% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +760.90% | — |
| Average volume | 274.80K | 23.94K |
| Shares outstanding | 9.95M | 11.57M |
| Employees | 18 | 1 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXMD has outperformed SCYX by 121.7 percentage points over the past year.
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
About TherapeuticsMD
TXMD stock →TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 1 employees
SCYX vs TXMD FAQ
Which is bigger, SCYNEXIS or TherapeuticsMD?
SCYNEXIS (SCYX) is larger, with a market capitalization of $41.99M compared with $23.26M for TherapeuticsMD (TXMD).
Which stock has performed better over the past year, SCYX or TXMD?
TXMD returned +89.62% over the past 12 months, compared with -32.11% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are SCYNEXIS and TherapeuticsMD in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.